More recently, our group also demonstrated that Fc-conjugated AXL-targeting single domain antibodies (sdAbs) acted synergistically in combination with the standard-of-care agent cytarabine in THP-1 and MOLM-13 AML cell lines [108]. This evidence concerns the gene AXL and acute myeloid leukemia.